Streetbeat News

Earnings

OIS

Oil States International reported Q3 2024 earnings per share of $0.04, missing the consensus estimate of $0.06. Sales were $174.35 million, below the expected $192.72 million, and down 10.26% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:04 am

BLCO

Bausch + Lomb reported an adjusted EPS of $0.17, excluding acquired IPR&D.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

OSK

Oshkosh Corporation reported Q3 2024 earnings per share of $2.93, slightly surpassing the analyst estimate of $2.92. The company's sales reached $2.741 billion, exceeding the expected $2.672 billion and marking a 9.21% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

CRTO

Criteo (NASDAQ:CRTO) reported Q3 2024 earnings per share of $0.96, surpassing the analyst estimate of $0.83, marking a 35.21% increase from last year. However, sales of $266.103 million slightly missed the $266.980 million estimate, though they increased by 8.44% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

CDW

CDW reported Q3 2024 earnings per share of $2.63, missing the analyst estimate of $2.85. Sales were $5.517 billion, below the expected $5.719 billion, and a 1.97% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

ADP

Automatic Data Processing (ADP) reported its Q1 2025 financial results, surpassing analyst expectations with an adjusted EPS of $2.33 against the estimated $2.21, and sales of $4.833 billion compared to the expected $4.774 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

OPCH

Option Care Health reported Q3 2024 earnings per share of $0.31, meeting analyst expectations. The company's sales were $1.279 billion, surpassing the $1.215 billion estimate and marking a 17.02% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

BPMC

Blueprint Medicines reported Q3 2024 results with a GAAP EPS of $(0.89), beating the estimate of $(0.96). Sales reached $128.18M, surpassing the $127.03M estimate. This marks a significant improvement from the previous year, with EPS losses reduced by 59.55% and sales increased by 126.61%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

GRMN

Garmin has raised its fiscal year 2024 outlook, increasing its adjusted EPS from $6.00 to $6.85 and sales from $5.95 billion to $6.12 billion. This adjustment is based on strong performance in the first three quarters of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am

KEX

Kirby Corporation reported its Q3 2024 financial results, with GAAP EPS of $1.55, surpassing the estimate of $1.47. The company's sales reached $831.1 million, also beating the expected $827.02 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:03 am